IDEAYA Biosciences Enters Material Definitive Agreement
Ticker: IDYA · Form: 8-K · Filed: Mar 12, 2024 · CIK: 1676725
| Field | Detail |
|---|---|
| Company | Ideaya Biosciences, Inc. (IDYA) |
| Form Type | 8-K |
| Filed Date | Mar 12, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $0.0001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, partnership
TL;DR
IDEAYA signed a big deal, details TBD.
AI Summary
IDEAYA Biosciences, Inc. entered into a material definitive agreement on March 8, 2024. The filing does not disclose specific details of the agreement, such as the counterparty or financial terms, but it is classified under 'Entry into a Material Definitive Agreement'.
Why It Matters
This filing indicates a significant new contract or partnership for IDEAYA Biosciences, which could impact its future operations and financial performance.
Risk Assessment
Risk Level: medium — The lack of specific details in the filing creates uncertainty about the nature and impact of the agreement.
Key Players & Entities
- IDEAYA Biosciences, Inc. (company) — Registrant
- March 8, 2024 (date) — Date of earliest event reported
- Delaware (jurisdiction) — State of incorporation
- 001-38915 (filing_id) — SEC File Number
- 47-4268251 (tax_id) — IRS Employer Identification Number
- 7000 Shoreline Court, Suite 350 (address) — Principal executive offices
- South San Francisco, California 94080 (address) — Principal executive offices
- (650) 443-6209 (phone_number) — Registrant's telephone number
FAQ
What is the nature of the material definitive agreement entered into by IDEAYA Biosciences, Inc.?
The filing states that IDEAYA Biosciences, Inc. entered into a material definitive agreement on March 8, 2024, but does not provide specific details about the agreement's terms, counterparty, or purpose.
Who is the counterparty to this material definitive agreement?
The filing does not disclose the name of the other party involved in the material definitive agreement.
What is the effective date of this agreement?
The earliest event reported is March 8, 2024, which is the date of the report and the date of the material definitive agreement.
Are there any financial implications mentioned for IDEAYA Biosciences, Inc. as a result of this agreement?
No specific financial terms, obligations, or expected impacts are detailed in this filing regarding the material definitive agreement.
What is the SEC filing number for this report?
The SEC file number for this 8-K report is 001-38915.
Filing Stats: 554 words · 2 min read · ~2 pages · Grade level 12.8 · Accepted 2024-03-12 06:04:16
Key Financial Figures
- $0.0001 — nge on which registered Common Stock, $0.0001 par value per share IDYA The Nasdaq
Filing Documents
- idya-20240308.htm (8-K) — 43KB
- idya-ex99_1.htm (EX-99.1) — 14KB
- img107722786_0.jpg (GRAPHIC) — 3KB
- 0000950170-24-029619.txt ( ) — 181KB
- idya-20240308.xsd (EX-101.SCH) — 28KB
- idya-20240308_htm.xml (XML) — 5KB
01 Entry into a Material Definitive Agreement
Item 1.01 Entry into a Material Definitive Agreement. On March 12, 2024, IDEAYA Biosciences, Inc. (the "Company") announced that it had entered into a Clinical Trial Collaboration and Supply Agreement (the "Agreement"), dated March 8, 2024, with MSD International Business GmbH ("MSD"), to evaluate the Company's investigational IDE161 compound in combination with KEYTRUDA (pembrolizumab) Merck's anti-PD-1 therapy (the "Study"). Pursuant to the Agreement, the Company is the sponsor of the Study and the Company will provide the Company's IDE161 compound and will pay for the costs of the Study. Merck will provide KEYTRUDA for the Study at no cost to the Company. The Company and MSD will jointly own clinical data from the Study and all inventions relating to the combined use of IDE161 and pembrolizumab. Each party retains commercial rights to its respective compounds, including with respect to use as a monotherapy or combination agent. The foregoing is only a summary description of the terms of the Agreement, does not purpose to be complete and is qualified in its entirety by reference to the Agreement, which will be filed as an exhibit to the Company's Quarterly Report on Form 10-Q for the fiscal quarter ending March 31, 2024. (d) Exhibits. Exhibit No. Description 99.1 Press Release dated March 12, 2024
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. IDEAYA BIOSCIENCES, INC. Date: March 12, 2024 By: /s/ Yujiro Hata Yujiro Hata President and Chief Executive Officer